- Home
- SMID vs IPHA Comparison
SMID vs IPHA Comparison
Compare SMID & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- IPHA
- Stock Information
- Founded
- SMID 1960
- IPHA 1999
- Country
- SMID United States
- IPHA France
- Employees
- SMID N/A
- IPHA N/A
- Industry
- SMID Building Materials
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SMID Industrials
- IPHA Health Care
- Exchange
- SMID Nasdaq
- IPHA Nasdaq
- Market Cap
- SMID 157.4M
- IPHA 160.1M
- IPO Year
- SMID 1995
- IPHA 2019
- Fundamental
- Price
- SMID $34.93
- IPHA N/A
- Analyst Decision
- SMID
- IPHA Strong Buy
- Analyst Count
- SMID 0
- IPHA 1
- Target Price
- SMID N/A
- IPHA $11.00
- AVG Volume (30 Days)
- SMID 22.0K
- IPHA 11.7K
- Earning Date
- SMID 08-13-2025
- IPHA 03-27-2025
- Dividend Yield
- SMID N/A
- IPHA N/A
- EPS Growth
- SMID 866.67
- IPHA N/A
- EPS
- SMID 1.45
- IPHA N/A
- Revenue
- SMID $78,508,000.00
- IPHA $20,831,349.00
- Revenue This Year
- SMID N/A
- IPHA $209.83
- Revenue Next Year
- SMID N/A
- IPHA $83.15
- P/E Ratio
- SMID $24.09
- IPHA N/A
- Revenue Growth
- SMID 31.77
- IPHA N/A
- 52 Week Low
- SMID $25.03
- IPHA $1.29
- 52 Week High
- SMID $51.96
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SMID 67.05
- IPHA 39.24
- Support Level
- SMID $32.38
- IPHA $1.71
- Resistance Level
- SMID $32.19
- IPHA $1.90
- Average True Range (ATR)
- SMID 1.54
- IPHA 0.09
- MACD
- SMID 0.57
- IPHA -0.00
- Stochastic Oscillator
- SMID 93.93
- IPHA 40.74
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.